What is SELLAS Life Sciences Group, Inc.'s G&A?

SELLAS Life Sciences Group, Inc. (SLS) reported G&A of $4.12M in Q1 2026.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

SELLAS Life Sciences Group, Inc. SLS G&A

G&A at other companies

Syndax PharmaceuticalsSNDX

$37.59M-8.4%

ImmunomeIMNM

$12.95M+21.1%

Arcus BiosciencesRCUS

$29M+3.6%

Cogent Biosciences, Inc.COGT

$28.24M+137%

Iovance Biotherapeutics, Inc.IOVA

$38.95M-11.1%

CRISPR TherapeuticsCRSP

$17.18M-11.0%

Other financials

Income statement

See full

Revenue-—

Gross profit-—

Operating income-$9.3M-52.6%

Net income-$8.4M-44.6%

EPS (diluted)-$0.05+28.6%

Balance sheet

See full

Cash & equivalents$107.1M+277%

Total debt$871.0K+0.1%

Total equity$107.4M+287%

Total assets$114.2M+227%

Cash flow

See full

Operating cash flow-$8.8M+2.5%

Valuation

See full

Market cap$1.78B+674%

Enterprise value$1.68B+826%

Profitability

See full

Gross margin90%-7.4pp

Operating margin-4,195%-4,591pp

Net margin-4,130.1%-4,444pp

FCF margin-300.5%—

Returns & leverage

See full

Return on equity-43.6%-17.9pp

Debt / equity0×0.0×

Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s G&A?: SELLAS Life Sciences Group, Inc. (SLS) reported G&A of $4.12M in Q1 2026.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.